Alterations in microRNA Expression during Hematopoietic Stem Cell Mobilization.
CD34+
hematopoietic stem cells
hsa-miR-146a-5p
miRNA
mobilization
multiple myeloma
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
15 Jul 2021
15 Jul 2021
Historique:
received:
03
06
2021
revised:
09
07
2021
accepted:
12
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
microRNAs play an important role in the regulation of gene expression, cell fate, hematopoiesis, and may influence the efficacy of CD34+ cell mobilization. The present study examines the role of hsa-miR-15a-5p, hsa-miR-16-5p, hsa-miR-34a-5p, hsa-miR-126-3p, hsa-miR-146a-5p, hsa-miR-155-5p, and hsa-miR-223-3p in the course of hematopoietic stem cell mobilization. The numbers of CD34+ cells collected in patients with hematological malignancies (39 multiple myelomas, 11 lymphomas) were determined during mobilization for an autologous hematopoietic stem cell transplantation. The miRNA level was evaluated by RT-PCR. Compared to baseline, a significant decline in hsa-miR-15a-5p, hsa-miR-16-5p, hsa-miR-126-3p, hsa-miR-146a-5p, and hsa-miR-155-5p was observed on the day of the first apheresis (day A). An increase was observed only in the expression of hsa-miR-34a-5p. On day A, a negative correlation was found between hsa-miR-15a-5p and hsa-miR-146a-5p levels and the number of CD34+ cells in peripheral blood. A negative correlation was observed between hsa-miR-146a-5p and the number of collected CD34+ cells after the first apheresis. Good mobilizers, defined according to GITMO criteria, demonstrated a lower hsa-miR-146a-5p level on day A than poor mobilizers. Patients from the hsa-miR-146a-5p "low expressors" collected more CD34+ cells than "high expressors". Our results suggest that the investigated miRNAs, especially hsa-miR-146a-5p, may influence the efficacy of HSC mobilization.
Identifiants
pubmed: 34356523
pii: biology10070668
doi: 10.3390/biology10070668
pmc: PMC8301406
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Uniwersytet Medyczny w Lodzi
ID : 503/1-093-01/503-11-004-18
Organisme : Uniwersytet Medyczny w Lodzi
ID : 503/6-086-01/503-61-001-19
Références
Biol Blood Marrow Transplant. 2014 May;20(5):630-9
pubmed: 24462744
PLoS One. 2015 Mar 20;10(3):e0119304
pubmed: 25793640
PLoS One. 2011;6(11):e27008
pubmed: 22073238
Mol Med. 2015 Apr 09;20:736-46
pubmed: 25730818
J Exp Med. 2001 May 7;193(9):1005-14
pubmed: 11342585
PLoS One. 2014 Feb 27;9(2):e90005
pubmed: 24587182
Oncol Lett. 2016 Nov;12(5):3531-3536
pubmed: 27900032
Exp Ther Med. 2016 Jul;12(1):396-404
pubmed: 27347068
Cancers (Basel). 2019 Feb 18;11(2):
pubmed: 30781685
Exp Ther Med. 2012 May;3(5):763-770
pubmed: 22969965
Biochim Biophys Acta. 2015 Mar;1849(3):353-66
pubmed: 25497370
Leukemia. 2011 Apr;25(4):729-33
pubmed: 21233833
J Intern Med. 2013 Sep;274(3):215-26
pubmed: 23772809
Stem Cells. 2011 May;29(5):847-57
pubmed: 21394831
J Cell Biochem. 2006 Oct 15;99(3):690-705
pubmed: 16888804
Front Genet. 2014 Jul 09;5:219
pubmed: 25071842
Genome Res. 2009 Jul;19(7):1175-83
pubmed: 19336450
Haematologica. 2012 Jun;97(6):818-26
pubmed: 22271895
Int J Oncol. 2016 May;48(5):1855-67
pubmed: 26936292
Angiogenesis. 2012 Mar;15(1):151-63
pubmed: 22249946
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5
pubmed: 17293455
Blood Cancer J. 2011 Jun;1(6):e26
pubmed: 22829170
Leuk Res. 2018 May 21;70:45-48
pubmed: 29807272
Biol Blood Marrow Transplant. 2014 Jul;20(7):986-91
pubmed: 24680978
Blood. 2009 Sep 17;114(12):2530-41
pubmed: 19602709
Cell Stem Cell. 2012 Dec 7;11(6):799-811
pubmed: 23142521
Stem Cells. 2014 Apr;32(4):902-12
pubmed: 24307639
Mol Cell Biol. 2008 Jul;28(14):4609-19
pubmed: 18474618
Biochim Biophys Acta. 2012 Oct;1823(10):1925-35
pubmed: 22867989
Elife. 2013 May 21;2:e00537
pubmed: 23705069
Bone Marrow Transplant. 2012 Mar;47(3):342-51
pubmed: 21625224
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Br J Haematol. 2018 Nov;183(3):428-444
pubmed: 30125933
Blood. 2009 Jun 25;113(26):6669-80
pubmed: 19401561
Sci Rep. 2016 Aug 24;6:32174
pubmed: 27552933
J Leukoc Biol. 2018 Sep;104(3):515-524
pubmed: 29969525
Ann Hematol. 2016 Jan;95(2):263-9
pubmed: 26611854
Oncotarget. 2013 Sep;4(9):1399-415
pubmed: 24009080
Int J Mol Sci. 2021 Feb 27;22(5):
pubmed: 33673480
Carcinogenesis. 2013 Feb;34(2):426-35
pubmed: 23104180
Eur J Haematol. 2018 May;100(5):426-435
pubmed: 29380440
Ann Hematol. 2017 Dec;96(12):2103-2112
pubmed: 28956132
Sci Rep. 2017 Dec 20;7(1):17949
pubmed: 29263373
Oncotarget. 2015 Sep 22;6(28):26508-18
pubmed: 26164366
J Clin Oncol. 2004 Mar 15;22(6):1095-102
pubmed: 15020611
Biomed Res Int. 2016;2016:9513037
pubmed: 27294145
Int J Clin Exp Pathol. 2020 Jan 01;13(1):89-98
pubmed: 32055277
Biomed Res Int. 2015;2015:497280
pubmed: 26221595
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1516-21
pubmed: 18227515
Nature. 2008 Feb 28;451(7182):1125-9
pubmed: 18278031
Exp Hematol. 2015 Oct;43(10):858-868.e7
pubmed: 26163797
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7140-E7149
pubmed: 28784800
Eur Rev Med Pharmacol Sci. 2017 Nov;21(22):5153-5159
pubmed: 29228427
PLoS One. 2014 Oct 14;9(10):e108468
pubmed: 25313822
Dev Cell. 2008 Aug;15(2):272-84
pubmed: 18694566
Blood. 2003 Jun 1;101(11):4569-75
pubmed: 12576322
Biomedicines. 2021 Mar 25;9(4):
pubmed: 33806113
Blood Rev. 2015 Jan;29(1):33-44
pubmed: 25263425
J Hematol Oncol. 2012 Mar 27;5:13
pubmed: 22453030
BMC Cancer. 2019 Jan 14;19(1):59
pubmed: 30642286
J Mol Diagn. 2015 Nov;17(6):669-78
pubmed: 26433312
Int J Mol Med. 2018 Sep;42(3):1577-1584
pubmed: 29901097
J Gastroenterol Hepatol. 2013 Jan;28(1):24-30
pubmed: 23094824
Leuk Lymphoma. 2016 Dec;57(12):2752-2762
pubmed: 27396981
Cell Death Differ. 2014 Feb;21(2):290-301
pubmed: 24141720
J Hematol Oncol. 2011 Sep 22;4:37
pubmed: 21936961
Leukemia. 2017 May;31(5):1247-1250
pubmed: 28174416
Nat Cell Biol. 2008 Jul;10(7):788-801
pubmed: 18568019